I and hope continues Eric during good healthy you, Thank be to morning. time. everyone and safe this
primarily I the EPS for XXXX. and let's margin takeaways sheet as detail. market review through numbers and Contract revenue and the QX first some our as revenues finally, we'll Generics We'll guidance quarter, balance So the in led take units strong review well will saw XXXX strong Manufacturing. where in we more saw by sales growth look performance, we Biologics at you growth and in profits, and
components treatment as COVID-XX the volumes the offset million diagnosis such GAAP our measures restrictions, $XX COVID described First on quarter. sales net patients, XX. summarized up revenues results in by of of and recorded in have reconciliation sales and customers of assessment related to are affected lower These QX, associated at home net financial elective to We dental, the been growth XX net and to organic procedures. due of veterinary estimated approximately our XX.X%. stay X with lower include pandemic are to and are of sales revenues $XXX.X representing by Slide Slides million, non-US
was increase. point saw year quarter, with profits. basis expansion adjusted XX.X% gross year. above profit to period XXX XX% And $XXX continue period million QX in in or We gross a our gross in from million improvement improvement recorded of of margin a operating $XXX.X see XX.X million last for last We this in same XX.X to the last year. million We XX.X% recorded profits same compared the profit,
a was from XX.X% increase of the year. margin XXX profit operating basis period adjusted last same Our point
adjusted grew XX% Finally diluted for EPS QX.
approximately tax in $X.XX of EPS Excluding grew stock benefit by QX, XX%.
organically XX.X% and market which Proprietary made sales quarter double in the Slide sales more Products solid had the X, across Moving up XX% units products, QX. quarter. of momentum by grew in digits Proprietary grew to throughout our than all Product High-value
Looking at the growth. strong of units, the the performance delivered market double-digit Biologics unit market
are and film led with experienced We offering. and Daikyo by many products West The biotech high Generics value growth and biopharma double-digit work coated customers unit FluroTec who using to sales. market continue product
and double sales Contract Our components. again once pharma digit low of units high-value and sales organic growth second sales FluroTec saw growth including for lead the had and And by led healthcare related devices. products services by diagnostic quarter, market Manufacturing digit single with Westar injection
revenue Sales by point. driven And $X.X growth. net X.X sales percentage reduction by COVID-XX $X.X reduced or rates currency changes million million On X, So profit? to growth Slide quarter. both in the growth, and approximately million and show the or including contributions what's volume in sales demand. million mix contributed Volume of price driving increases $XX foreign a points exchange of percentage the percentage we growth in $XX.X related XX.X or of points of two contributed
manufacturing project products, production gross of efficiencies quarter XXXX, and achieved Looking XXXX. XX% the profit shows margin XXX the XX.X% gross above profit margin up XXX in from margin at gross of points for second Proprietary by There The the plant basis XX% XXX was to second efficiencies key to offset of XXX favorable QX XX.X% quarter profit consolidated result is X gross one-time margin mix a QX impact product positive overhead engineering XXXX. continued partially quarter performance, margin second was margin improvement due margin the and costs. of points Products work. primarily of Slide The our increased on basis utilization. a improved second drivers approximately driven XXXX. margin in a in sold improvement high-value increases, was above Proprietary profit quarter Contract achieved points were in Products sales price of basis for by the
took to Our attributable One gross from million asset was adjusted XX.X% for one-time period the largely to This operating included we a point is in XXX charge last profit point impairment. expansion. same note, profit margin other expense. our $X.X basis of operating increase of a year,
cash year-to-date done of for and Now, cash we've same have listed million last On Slide let's flow key our we XXXX, for increase the cash the Operating more XX% an of balance a sheet million XX.X review was how some XX, increase. at year, flow business. metrics. the compared $XXX.X period terms look generating in to
XX, capital stock increased XX.X higher million in levels increasing as due was the spending safety accounts due than XX, December year inventory the at at quarter. million activity. and and last in receivable result XX.X XXXX, DPO guidance. June and to year-to-date with higher improved same to an line of Both sales increase primarily million, was XXXX, DSO than capital $XX.X mainly $XXX.X Our Working our in million of a period
at balance positive June XXXX operating million X.X primarily due cash results. Our XX December million our balance, was more than $XXX.X to of our
strong. and resources capital including liquidity financial Our remain overall
revenues incremental provides between high-level There a billion. $XX in and current net Turning be a will of million includes rates. headwind guidance an to million. estimated of sales XXXX $XX $X.XXX summary. estimated based exchange range of net billion guidance, COVID XX Slide Full year $X.XXX This on foreign is
We growth comps. sales to Manufacturing to result $X.XX billion expect of than of billion to HX compares X%. We in growth tougher prior to versus do a of XX.X%. organic expect Contract HX less approximately be growth be $X.XX guidance as and This
We guidance of expect reported guidance range our of $X.XX, full prior a $X.XX. year $X.XX $X.XX EPS to in be to XXXX to compared diluted to
impact headwind on at revised HVP $XXX tax from to to As includes million. $XX impact COVID-XX existing This some from has million capacity FX to There you current guidance. guidance approximately EPS are EPS XXX your $X.XX exchange Eric manufacturing of also of previous want as compensation. to based rates. benefits stock-based XXX guidance currency attention XXXX to million discussed, bring The raised On anticipated I to review demand. compares elements an we on sites $X.XX vaccine key meet HX Estimated has foreign are guidance expanding CapEx our to our our million. our
in for So margin top margin, EPS in and cash the profit growth the profit Contract Proprietary growth to and quarter, line in and growth manufacturing, key summarize operating operating flow. takeaways both in second gross adjusted free growth diluted strong improvement,
Our long-term turn to EPS back construct the remains to sales I'd over at approximately expansion. continued call now organic like growth Eric. and X% to X%